WASHINGTON , March 21, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2024 on Tuesday, April 23, 2024
Zacks.com users have recently been watching Danaher (DHR) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The latest trading day saw Danaher (DHR) settling at $251.68, representing a -0.81% change from its previous close.
The latest trading day saw Danaher (DHR) settling at $251.47, representing a +0.83% change from its previous close.
Danaher (DHR) gains from strength in academic and life science research markets, Abcam buyout and pro-investor policies. However, softness in its Biotechnology and Diagnostics units is concerning.
Danaher (DHR) closed the most recent trading day at $252.80, moving -0.35% from the previous trading session.
Danaher (DHR) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Danaher (DHR) reported earnings 30 days ago. What's next for the stock?
Danaher (DHR) reachead $255.71 at the closing of the latest trading day, reflecting a +0.33% change compared to its last close.
ITT's Q4 revenues increase 7% year over year, driven by higher Friction original equipment volumes in the Motion Technologies segment and pricing actions in the Connect & Control Technologies segment.
While Danaher (DHR) surpasses Q4 earnings and revenue estimates, its performance is hurt by a decrease in the sale of COVID-related products and weak demand in the Biotechnology segment.
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Danaher (DHR) came out with quarterly earnings of $2.09 per share, beating the Zacks Consensus Estimate of $1.90 per share. This compares to earnings of $2.87 per share a year ago.
Danaher (DHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Danaher's (DHR) Q4 earnings are likely to have been hurt by weakness in the Biotechnology and Diagnostics units owing to lower sales of COVID-related products. Improving supply chains and strong price
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE